<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Guidelines on oral anticoagulation with warfarin - fourth edition.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M, British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011 Aug;154(3):311-24. [111 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21671894&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006 Feb;132(3):277-85.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Acute myocardial infarction of unspecified site, episode of care unspecified  (410.90); Acute venous embolism and thrombosis of unspecified deep vessels of lower extremity  (453.40); Atrial fibrillation  (427.31); Head injury, unspecified  (959.01); Hemorrhage, unspecified  (459.0); Other pulmonary embolism and infarction  (415.19); Other venous embolism and thrombosis of unspecified site  (453.9); Peripheral vascular disease, unspecified  (443.9); Primary hypercoagulable state  (289.81)"/><FieldValue Value="MSH: Administration, Oral ; Anticoagulants ; Antiphospholipid Syndrome ; Aspirin ; Atrial Fibrillation ; Blood Coagulation Factors ; Cardiomyopathies ; Coagulants ; Coronary Artery Disease ; Coronary Thrombosis ; Craniocerebral Trauma ; Drug Therapy, Combination ; Electric Countershock ; Factor VIIa ; Heart Valve Diseases ; Heart Valve Prosthesis ; Hemorrhage ; Heparin, Low-Molecular-Weight ; International Normalized Ratio ; Medical History Taking ; Medication Therapy Management ; Myocardial Infarction ; Neoplasms ; Perioperative Care ; Peripheral Vascular Diseases ; Plasma ; Platelet Aggregation Inhibitors ; Pulmonary Embolism ; Self Care ; Thromboembolism ; Thrombolytic Therapy ; Thrombophilia ; Thrombosis ; Venous Thromboembolism ; Venous Thrombosis ; Vitamin K ; Warfarin "/><FieldValue Value="MTH: Acute myocardial infarction ; Anastomosis of artery with bypass graft (procedure) ; Anticoagulants ; Antiphospholipid Syndrome ; Aspirin ; Atrial Fibrillation ; Blood Coagulation Factor ; Cardiomyopathies ; Combination Drug Therapy ; Coronary Artery Disease ; Deep Vein Thrombosis ; Electric Countershock ; Factor VIIa ; Fresh frozen plasma ; HEAD INJURY ; Heart Valve Diseases ; Heart Valve Prosthesis ; Hemorrhage ; Heparin, Low-Molecular-Weight ; International Normalized Ratio ; Malignant Neoplasms ; Myocardial Infarction ; Neoplasms ; Peripheral Vascular Diseases ; Plasma ; Platelet Aggregation Inhibitors ; Pulmonary Embolism ; Self-care interventions ; Thromboembolism ; Thrombophilia ; Thrombosis ; Venous Thromboembolism ; Venous Thrombosis ; Vitamin K ; Warfarin "/><FieldValue Value="PDQ: acetylsalicyclic acid ; cancer ; thromboembolism ; thrombolytic therapy ; warfarin "/><FieldValue Value="SNOMEDCT_US: Acute myocardial infarction  (57054005); Anticoagulant  (372862008); Anticoagulant  (81839001); Antiphospholipid syndrome  (26843008); Arterial bypass graft  (116360008); Arterial bypass graft  (34518000); Arterial embolus and thrombosis  (266262004); Aspirin  (387458008); Aspirin  (7947003); Atrial fibrillation  (49436004); Blood clotting factor  (350475008); Cardiac valve prosthesis  (25510005); Cardiomyopathy  (57809008); Cardiomyopathy  (85898001); Cardioversion  (250980009); Coagulant  (15117003); Coagulant  (373746004); Coronary artery thrombosis  (398274000); Deep venous thrombosis  (128053003); Disorder of coronary artery  (414024009); Factor VIIa products  (319918003); Factor VIIa products  (73801006); Fresh frozen plasma  (346447007); Heart valve disorder  (368009); Hemorrhage  (131148009); Hemorrhage  (50960005); Injury of head  (82271004); International normalized ratio  (165581004); International normalized ratio  (1951000175101); Low molecular weight heparin  (373294004); Low molecular weight heparin  (87233003); Malignant neoplastic disease  (363346000); Medication administration: oral  (386359008); Myocardial infarction  (22298006); Neoplasm  (108369006); Perioperative care  (133897009); Peripheral vascular disease  (400047006); Plasma  (419185008); Plasma  (50863008); Pulmonary embolism  (59282003); Self-care interventions  (384758001); Thromboembolic disorder  (13713005); Thromboembolic disorder  (371039008); Thrombolytic therapy  (426347000); Thrombophilia  (234467004); Thrombophilia  (76612001); Thrombosis  (118927008); Thrombosis  (264579008); Thrombosis  (439127006); Venous thrombosis  (111293003); Vitamin K  (65183007); Vitamin K  (74226000); Warfarin  (372756006); Warfarin  (48603004)"/><FieldValue Value="SPN: VALVE, PROSTHESIS "/><FieldValue Value="UMD: Prostheses, Cardiac Valve  (13-138)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conditions requiring oral anticoagulation therapy, including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Venous thromboembolism (VTE) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antiphospholipid syndrome (APS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Atrial fibrillation (AF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conditions requiring cardioversion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Valvular heart disease and&amp;nbsp;prosthetic valves &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Peripheral vascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Myocardial infarction and cardiomyopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary embolism (PE) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Deep vein thrombosis (DVT), including cancer-associated DVT &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Critical Care" /><FieldValue Value="Family Practice" /><FieldValue Value="Hematology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Surgery" /><FieldValue Value="Thoracic Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide healthcare professionals with clear guidance on the indications for and management of patients on warfarin&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;People in the United Kingdom with conditions requiring anticoagulation prophylaxis or therapy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Warfarin dose based on international normalized ratio (INR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duration of anticoagulation for pulmonary embolism and lower-limb deep vein thrombosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Induction of anticoagulation (i.e., loading doses) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Peri-operative anticoagulation (bridging therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reversal of anticoagulation for emergency surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of bleeding or high INR in the absence of bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bridging therapy for sub-therapeutic anticoagulation in the first month after an acute venous thromboembolism &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combination warfarin and antiplatelet therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of head injuries &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulant monitoring and dose adjustment (manual dosing, computer-assisted dosing, patient self-management, vitamin K intake, patient records, drug interactions) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following were considered but not recommended: genotype-guided initiation as response to a standard dosing algorithm, recombinant factor VIIa for emergency anticoagulation reversal, long-term anticoagulation in selected situations.&lt;/p&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Rates of thrombosis, myocardial infarction, and stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bleeding rates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guidance is updated with reference to relevant publications since 2005. Publications known to the writing group were supplemented with additional papers identified by searching PubMed for publications in the last 5 years using the key word warfarin and limits clinical trial, randomized control trial, meta-analysis, humans, core clinical journals, and English language.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(A) High&lt;/strong&gt; Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(B) Moderate&lt;/strong&gt; Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision - wide confidence intervals or methodological flaws - e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(C) Low&lt;/strong&gt; Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The writing group was selected to be representative of United Kingdom (UK) based experts. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong (grade 1)&lt;/strong&gt;: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak (grade 2)&lt;/strong&gt;: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Computerized dosing has been shown to increase the overall percentage time for which patients are in their target international normalized ratio (INR) range and in some studies to reduce the frequency of testing of patients. Furthermore, it has been shown to significantly reduce the risk of bleeding and thromboembolic events and overall is a more cost-effective option to manual dosing.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was reviewed by a sounding board of approximately 50 United Kingdom (UK) haematologists, the British Committee for Standards in Haematology (BCSH), the British Cardiovascular Society and the British Society for Haematology Committee and comments incorporated where appropriate.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the quality of the evidence (&lt;strong&gt;A-C&lt;/strong&gt;) and strength of recommendation (strong [grade &lt;strong&gt;1&lt;/strong&gt;], weak [grade &lt;strong&gt;2&lt;/strong&gt;]) are given at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Indications for Warfarin and Recommended Target International Normalized Ratio (INR)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Venous Thromboembolism (VTE)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;First episodes of VTE should be treated with an INR target of 2.5 (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Warfarin used for treatment of VTE should be introduced along with parenteral anticoagulation (&lt;strong&gt;1A&lt;/strong&gt;) which should continue for at least 5 d and until the INR is&amp;nbsp;&amp;ge;2 for at least 24 h (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recurrent VTE whilst anticoagulated and within the therapeutic range should be managed by increasing the INR target to 3.5 (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antiphospholipid Syndrome (APS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The target INR should be 2.5 in patients with APS (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Atrial Fibrillation (AF)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with AF who require warfarin for the prevention of cardio-embolic stroke should have an INR target of 2.5 (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cardioversion&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients undergoing elective cardioversion should be anticoagulated with warfarin for at least 3 weeks prior to and 4 weeks post cardioversion with a target INR of 2.5 (&lt;strong&gt;2C&lt;/strong&gt;). To minimize cardioversion cancellations due to low INRs on the day of the procedure a target INR of 3.0 can be used prior to the procedure. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Valvular Heart Disease and Prosthetic Valves&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mitral Stenosis or Regurgitation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with mitral stenosis or regurgitation who have atrial fibrillation (&lt;strong&gt;1A&lt;/strong&gt;) or a history of systemic embolism (&lt;strong&gt;1A&lt;/strong&gt;) or left atrial thrombus (&lt;strong&gt;1A&lt;/strong&gt;) or an enlarged left atrium (&lt;strong&gt;2C&lt;/strong&gt;) should receive warfarin with an INR target of 2.5. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mechanical Prosthetic Heart Valves&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The recommended target INRs for mechanical heart valves are given in the table below.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table: Recommended target INRs for mechanical heart valves (2B)&lt;/strong&gt; [adapted from Vahanian et al., European Heart Journal, 2007:28, 230&amp;ndash;268]&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;5&quot; summary=&quot;Table: Indications for Oral Anticoagulation, Target International Normalised Ratio (INR) and Grade of Recommendations&quot; cellpadding=&quot;9&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th&gt;Prosthesis &lt;br /&gt;&#xD;&#xA;            Thrombogenicity*&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;INR target &lt;br /&gt;&#xD;&#xA;            No patient risk factors&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;INR target&lt;br /&gt;&#xD;&#xA;            Patient-related risk factors&amp;dagger;&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2.5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3.0&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Medium&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3.0&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3.5&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3.5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3.5&amp;Dagger;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Prosthesis thrombogenicity: Low: Carbomedics (aortic position), Medtronic Hall, St Jude Medical (without silzone); Medium: Bjork-Shiley, other bileaflet valves; High: Starr-Edwards, Omniscience, Lillehei-Kaster.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Patient-related risk factors for thrombosis: Mitral, tricuspid or pulmonary position; Previous arterial thromboembolism; Atrial fibrillation; Left atrium diameter &amp;gt;50 mm; Mitral stenosis of any degree; Left ventricular ejection fraction &amp;lt;35%; Left atrial dense spontaneous echo contrast.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;Dagger;Was 4.0 in Vahanian et al (2007).&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In situations where an embolic event occurs during anticoagulation within target, elevation of the INR target or the addition of anti-platelet drugs should be considered (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Bioprosthetic Heart Valves&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with a bioprosthesis in the mitral position should receive 3 months of anticoagulation with warfarin with an INR target of 2.5 (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a bioprosthetic valve and a history of systemic embolism should have at least 3 months of anticoagulation with warfarin with an INR target of 2.5 (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a bioprosthetic valve and left atrial thrombus at surgery should receive warfarin until the clot has resolved with an INR target of 2.5 (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with bioprosthetic valves and other prothrombotic risk factors, such as atrial fibrillation and low ventricular ejection fraction, should receive warfarin with an INR target of 2.5 (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Peripheral Vascular Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with intermittent claudication should not routinely be treated with anticoagulants (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who suffer acute arterial embolism and proceed to embolectomy should be considered for long-term anticoagulation with warfarin with an INR target of 2.5 (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Myocardial Infarction and Cardiomyopathy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When warfarin is used following myocardial infarction, the INR target for anticoagulation is 2.5 (&lt;strong&gt;2A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with dilated cardiomyopathy who are anticoagulated to prevent systemic embolism should have an INR target of 2.5 (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Duration of Anticoagulation for Pulmonary Embolism (PE) and Lower Limb Deep Vein Thrombosis (DVT)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Duration of Initial Anticoagulation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with proximal DVT or pulmonary embolism should be treated for at least 3 months (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If a diagnostic strategy that identifies isolated calf vein DVT is employed, treatment of such clots can be restricted to 6 weeks (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with cancer-associated VTE should initially be treated for 6 months with therapeutic dose low molecular weight heparin (LMWH) rather than warfarin (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Continued Anticoagulation Beyond the Initial Period of 3 Months&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Long-term anticoagulant therapy is not recommended in patients with VTE provoked by surgery (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term anticoagulant therapy is not recommended in patients with VTE provoked by non-surgical transient trigger factors (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with unprovoked proximal DVT or pulmonary embolism should be considered for long-term anticoagulation, taking into account information that may help predict risk of recurrence and risk of bleeding in the individual patient (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term anticoagulant therapy is not recommended in patients with VTE confined to the calf (i.e., not extending into the popliteal vein) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Initiation of Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rapid Induction Regimens for Patients with Acute Thrombosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Overall there is no evidence to suggest a 10 mg loading dose is superior to a 5 mg loading dose. However in the elderly lower initiation doses or age-adjusted doses may be more appropriate as they lead to fewer high INRs (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence to warrant genotype-guided initiation as response to a standard dosing algorithm can equally accurately predict maintenance dose (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Induction of Anticoagulation in Outpatients with Atrial Fibrillation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;For outpatients who do not require rapid anticoagulation a slow-loading regimen is safe and achieves therapeutic anticoagulation in the majority of patients within 3&amp;ndash;4 weeks (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Peri-operative Anticoagulation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pre-operative bridging carries a low risk of bleeding but the use of post-operative bridging requires careful consideration due to the high risk of bleeding. The authors recommend that post-operative bridging should not be started until at least 48 h after high bleeding risk surgery (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with VTE more than 3 months earlier can be given prophylactic dose low molecular weight heparin (or a suitable alternative) rather than bridging therapy (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with low risk AF (no prior stroke or transient ischaemic attack [TIA]) do not require bridging therapy (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a bileaflet aortic mechanical heart valve (MHV) with no other risk factors do not require bridging (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a VTE within the previous 3 months, patients with AF and previous stoke or transient ischaemic attack or multiple other risk factors, and patients with a mitral mechanical heart valve should be considered for bridging therapy (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Management of Bleeding and of High INR in the Absence of Bleeding&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Major Bleeding&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;All hospitals managing patients on warfarin should stock a licensed four-factor prothrombin complex concentrate (PCC) (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Emergency anticoagulation reversal in patients with major bleeding should be with 25&amp;ndash;50 u/kg four-factor PCC and 5 mg intravenous vitamin K (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recombinant factor VIIa is not recommended for emergency anticoagulation reversal (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fresh frozen plasma produces suboptimal anticoagulation reversal and should only be used if PCC is not available (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Non-Major Bleeding&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulation reversal for non-major bleeding should be with 1&amp;ndash;3 mg intravenous vitamin K (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;INRs &amp;gt;5.0 and &amp;gt;8.0 in Non-Bleeding Patients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with an INR &amp;gt;5.0 but who are not bleeding should have 1&amp;ndash;2 doses of warfarin withheld and their maintenance dose should be reduced (&lt;strong&gt;1B&lt;/strong&gt;). The cause of the elevated INR should be investigated (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with an INR &amp;gt;8.0 should receive 1&amp;ndash;5 mg of oral vitamin K (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Emergency Surgery for Patients on Warfarin&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;For surgery that requires reversal of warfarin and that can be delayed for 6&amp;ndash;12 h, the INR can be corrected by giving intravenous vitamin K. For surgery that requires reversal of warfarin and which cannot be delayed, for vitamin K to have time to take effect the INR can be corrected by giving PCC and intravenous vitamin K. PCC should not be used to enable elective or non-urgent surgery (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Head Injury in Patients on Warfarin&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;All patients on warfarin presenting to Accident and Emergency departments with head injury should have their INR measured as soon as possible (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A lower threshold for performing a head computed tomography (CT) scan should be used for patients on warfarin (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on warfarin presenting with a strong suspicion of intracerebral bleed should have their anticoagulation reversed before the results of any investigations (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Management of Sub-Therapeutic Anticoagulation in the First Month After Acute VTE&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that bridging therapy be considered if the INR becomes significantly sub-therapeutic within the first month of an acute VTE (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Combination Warfarin and Antiplatelet Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patients on Antiplatelet Therapy who Develop an Indication for Warfarin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients receiving an anti-platelet agent as primary prophylaxis for cardiovascular disease (CVD) on developing an indication for warfarin should stop their antiplatelet agent (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with peripheral artery disease or previous ischaemic stroke on antiplatelet therapy should stop this agent if warfarin is commenced (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on aspirin or clopidogrel as secondary prophylaxis with stable ischaemic heart disease (often defined as &amp;gt;12 months following acute myocardial infarction) should stop their antiplatelet agent while being treated with warfarin (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on a single antiplatelet agent &amp;lt;12 months following an acute coronary syndrome (ACS), who require to start warfarin therapy should continue aspirin therapy until 12 months post ACS, unless they are regarded as having a high bleeding risk (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on aspirin and clopidogrel, following an ACS or stent placement, who develop an indication for warfarin should be carefully assessed for bleeding risk and discussed with their cardiologist, with a view to introducing warfarin and minimizing the duration of triple therapy (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When combined warfarin and single antiplatelet agent are indicated, consideration should be given to use of aspirin given the higher bleeding risk associated with clopidogrel (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patients on Warfarin Who Develop an Indication for Antiplatelet Agents&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients requiring a coronary artery stent, should be considered for bare metal stent (rather than drug-eluting stent) which would only necessitate triple therapy for 4 weeks, followed by aspirin and warfarin to 12 months (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who do not undergo percutaneous coronary intervention (PCI) should be considered for 4 weeks triple therapy, after which clopidogrel should be stopped, and aspirin continued for a further 11 months (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Anticoagulant Monitoring and Dose Adjustment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drug Interactions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;For patients on warfarin, computer-assisted dosing is superior to manual dosing (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Self-testing and self-management of warfarin is associated with improved anticoagulant control but may not be suitable for most patients (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All patients on warfarin must have a written record of their results and dose changes (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In individuals with an unstable INR, supplementing the diet with 100&amp;ndash;150 &amp;micro;g vitamin K may improve anticoagulant control (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All patients on warfarin who are prescribed a drug that may interact with it should have an INR performed after 3&amp;ndash;5 d (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(A) High&lt;/strong&gt; Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(B) Moderate&lt;/strong&gt; Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision - wide confidence intervals or methodological flaws - e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(C) Low&lt;/strong&gt; Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong (grade 1)&lt;/strong&gt;: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak (grade 2)&lt;/strong&gt;: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reduction in thromboembolisms and other morbidities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction in excess bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction in delays of cardioversion and surgical procedures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improved survival rates &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology nor the publishers accept any legal responsibility for the content of these guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M, British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011 Aug;154(3):311-24. [111 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21671894&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2006 Feb (revised 2011 Aug)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="British Committee for Standards in Haematology - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Committee for Standards in Haematology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Haemostasis and Thrombosis Task Force&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: David Keeling, Oxford Radcliffe Hospitals, Oxford; Trevor Baglin, Addenbrooke's Hospital, Cambridge; Campbell Tait, Glasgow Royal Infirmary, Glasgow; Henry Watson, Aberdeen Royal Infirmary, Aberdeen; David Perry, Addenbrooke's Hospital, Cambridge; Caroline Baglin, Addenbrooke's Hospital, Cambridge; Steve Kitchen, Royal Hallamshire Hospital, Sheffield, UK; Michael Makris, Royal Hallamshire Hospital, Sheffield, UK&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All authors made a declaration of interests to the British Committee for Standards in Haematology.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006 Feb;132(3):277-85.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.bcshguidelines.com/documents/warfarin_4th_ed.pdf&quot; title=&quot;BCSH Web site&quot;&gt;British Committee for Standards in Haematology Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the British Committee for Standards in Haematology; Email: &lt;a href=&quot;mailto:bcsh@b-s-h.org.uk&quot;&gt;bcsh@b-s-h.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on May 22, 2008. This NGC summary was updated by ECRI Institute on February 14, 2012. The updated information was verified by the guideline developer on February 17, 2012. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the British Committee for Standards in Haematology. For more information, contact the BCSH Secretary, 100 White Lion Street, London, UK, N1 9PF; Email: &lt;a href=&quot;mailto:bcsh@b-s-h.org.uk&quot;&gt;bcsh@b-s-h.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
